• Subscribe
  • Register for free Content
  • Cart
  • Login
  • Browse by Topic
    • 13 Reasons Why
    • Abstinence
    • Acamprosate
    • Addiction
    • Addiction Treatment
    • Addyi
    • Adhansia XR
    • ADHD
    • Adherence
    • adolescents
    • Adult ADHD
    • Adverse Childhood Experiences (ACES)
    • Affordable Care Act (ACA)
    • Agitation
    • air pollution
    • Akathisia
    • Alcohol
    • Alcohol Use
    • Alcohol use disorder
    • Alcoholism
    • Alpha Agonists
    • Alternative treatments
    • Amantadine
    • amphetamine
    • Amphetamines
    • Anorexia Nervosa
    • Antidepressant Augmentation
    • Antidepressants
    • Antipsychotic
    • Antipsychotics
    • Anxiety
    • Anxiety Disorder
    • APA CE Post-Test
    • Aripiprazole
    • ArModafinil
    • Asenapine
    • Assessment
    • asthma
    • atamoxetine
    • attention
    • Attention Deficit Hyperactivity Disorder
    • Atypical Antipsychotics
    • Austedo
    • Autism
    • Autism Spectrum Disorder
    • Autism Spectrum Disorder
    • Autism Spectrum Disorder autism spectrum disorder
    • Behavior therapy
    • Behavioral addiction
    • Behavioral therapy
    • Behavioral treatment
    • Belsomra
    • Benzodiazepines
    • Beta-blockers
    • Billing
    • Bipolar Depression
    • Bipolar Disorder
    • Bipolar II
    • Board Certification
    • Borderline Personality Disorder
    • BPD
    • Brain Devices
    • Brief psychotherapy
    • Brief Strategic Family Therapy (BFST)
    • Bullying
    • Buprenorphine
    • Bupropion
    • C-Reactive Protein
    • Caffeine
    • CAM Treatments
    • Cannabidiol
    • Cannabis
    • Caplyta
    • Carbamazepine
    • Cardiovascular
    • Cariprazine
    • Chantix
    • Child and adolescent
    • Child Psychiatry
    • Child Psychiatry
    • children
    • Chokroverty
    • Citalopram
    • Clinical practice
    • Clozapine
    • CME Post-Test
    • Co-occurring disorders
    • Cocaine
    • Cognition
    • Cognitive Behavioral Therapy
    • Cognitive Decline
    • cognitive impact
    • Cognitive Rehabilitation Therapy (CRT)
    • Collaborative care
    • community trauma
    • Comorbidity
    • Complementary treatments
    • Complimentary treatments
    • Computer addiction
    • Computers in Psychiatric Practice
    • Conduct Disorder
    • Confidentiality
    • Connect
    • Connection
    • Connections
    • Contagion
    • Coronavirus
    • Cosmetic pharmacology
    • COVID-19
    • COVID19
    • Crime
    • Criminal behavior
    • Crisis intervention
    • Crocus Sativus
    • CRP
    • Cultural Competence
    • Culture
    • Cymbalta
    • Dayvigo
    • Delusional Disorder
    • Dementia
    • Deplin
    • Deprescribing
    • Depression
    • Depressive Disorder
    • Deutetrabenazine
    • Diagnosis
    • Diagnostic Testing
    • Disaster
    • Disparities
    • Diversity
    • Dopamine
    • DSM
    • Dual diagnosis
    • Duloxetine
    • Dyslexia
    • Dysregulation
    • E-Cigarettes
    • Eating Disorders
    • eCigarettes
    • ECT
    • Effexor
    • efficacy
    • electronic use
    • emergent suicidality
    • Emotional dysregulation
    • End of Life Care
    • Engagement
    • Escitalopram
    • Esketamine
    • eTNS
    • Exercise
    • Existing marijuana
    • expressed emotion
    • extended-release
    • Falls
    • Family Separation
    • FDA Warnings
    • Female hypoactive sexual desire disorder
    • Female Issues in Psychiatry
    • Fluoxetine
    • Folate
    • Folic Acid
    • Free Articles
    • gabapentin
    • GAD
    • Gender
    • Gender & Sexuality
    • Gender Diverse
    • Gender Dysphoria
    • Gender Identity
    • Generalized Anxiety Disorder
    • Generics
    • GeneSight
    • Genetic Testing
    • Genetics and Psychiatry
    • Geriatric Psychiatry
    • Ginkgo
    • Guanfacine
    • Hair loss
    • Harm reduction
    • Head Trauma
    • Health Apps
    • Heart health
    • Heart rate
    • Hepatitis
    • Heroin
    • HIPAA
    • Histamine
    • HIV
    • Hormone Replacement Therapy
    • Hypnotics
    • Hypomania
    • Incarceration
    • Inflammation
    • Ingrezza
    • Inpatient Psychiatry
    • inquiry
    • Insomnia
    • Insurance
    • Internet
    • Interpreter
    • Intervention
    • Irritability
    • Keppra
    • Ketamine
    • l-methylfolate
    • Laboratory Testing in Psychiatry
    • Lamictal
    • Lamotrigine
    • Language
    • Lavender
    • Learning & Developmental Disabilities
    • Legal issues
    • Lemborexant
    • Levetiracetam
    • LGBT
    • LGBTQ+
    • Life coaching
    • Life expectancy
    • Light and Dark Therapy
    • Light therapy
    • Lightbox
    • Literacy
    • Lithium
    • Longevity
    • Low libido
    • Lumateperone
    • Lurasidone
    • Lyrica
    • Management
    • Mania
    • MAOIs
    • Marijuana
    • Media
    • Medical Comorbidities
    • Medication
    • Medication adherence
    • Melatonin
    • Meta-analysis
    • Metabolic syndrome
    • Metformin
    • Methadone
    • methylfolate
    • methylphenidate
    • Micronutrients
    • Mind-Gut Connection
    • Mindfulness
    • Minority
    • Mirtazapine
    • Mixed Features
    • Modafinil
    • Mood Stabilizers
    • Mortality
    • Motivational Interviewing
    • Naloxone
    • Naltrexone
    • Narcolepsy
    • Natural Medications
    • natural treatments
    • Negative Symptoms
    • Netflix
    • Neurology
    • Neuroscience in Psychiatry
    • Neurotoxicity
    • New York
    • News of Note
    • Nightmares
    • Norepinephrine
    • Nortriptyline
    • Novel Medications
    • Nuedexta
    • Nuplazid
    • Nutrition
    • Nuvigil
    • Obesity
    • OCD
    • olanzapine
    • online therapy
    • Opioid epidemic
    • Opioid Use Disorder
    • Opioids
    • Oral Contraceptives
    • Orexin
    • Orthostasis
    • Outpatient
    • Overdose
    • Oxcarbazepine
    • Pain
    • pandemic
    • Panic Disorder
    • Parenting Strategies
    • Parkinson’s
    • Parkinson’s Disease
    • Paroxetine
    • Particulate matter
    • Patch
    • Patient relationship
    • pediatric
    • Perseveration
    • Perseverative Behavior
    • Personality Disorders
    • Pharmaceutical Industry
    • Pharmacology
    • Pharmacology Tips
    • Pharmacy
    • phonemic awareness
    • Phonics
    • Physician assisted suicide
    • PICOT
    • Pimozide
    • Pitolisant
    • Podcast
    • polypharmacy
    • Postpartum Depression
    • Potency
    • Practice Tools and Tips
    • Practice Tools and Tips
    • Pramipexole
    • Prazosin
    • Pregabalin
    • Pregnancy
    • prescribing patterns
    • Prescription costs
    • Prevention
    • Primary care
    • Prison
    • Prodrome
    • Prolonged exposure
    • Promotoras
    • Pronouns
    • Provigil
    • Prozac
    • pseudobulbar affect
    • Psychiatric interviewing
    • Psychological First Aide
    • Psychopharm Myths
    • Psychopharmacology
    • Psychopharmacology Tips
    • Psychosis
    • Psychotherapy
    • Psychotherapy
    • Psychotic Depression
    • Psychotropic medication
    • PTSD
    • Public health
    • Quetiapine
    • Randomized controlled trial
    • rapid naming
    • Reading
    • Reading disorder
    • Reading Disorders
    • Reading remediation
    • Red Cross
    • Registered Articles
    • Relationships
    • Remediation
    • Repetitive Behavior
    • Repetitive behaviors
    • Research
    • Research Update
    • Research Updates
    • retention
    • Retirement
    • Risk
    • Risk Management
    • Risperidone
    • Ritalin
    • rTMS
    • safety
    • Saffron
    • Saphris
    • Schizophrenia
    • School Refusal
    • Seasonal Affective Disorder
    • Secuado
    • Self-injury
    • Self-Regulation
    • Serotonin Specific Reuptake Inhibitors (SSRIs)
    • Sertraline
    • Sex Therapy
    • Sexual Dysfunction
    • Sexual Side Effects
    • Side Effects
    • Silexan
    • Skype
    • Sleep
    • Sleep Apnea
    • Sleep Disorders
    • Smoking Cessation
    • Smoking Cessation Agents
    • smoking cessations
    • Social Anxiety Disorder
    • social cohesion
    • Special populations
    • SSRIs
    • Stereotypical Behavior
    • steroids
    • Stigma
    • stimulant
    • Stimulants
    • structured literacy
    • Suboxone
    • Substance Abuse
    • Substance Abuse
    • Substance Use
    • Substance Use Disorder
    • Substance use disorders
    • Suicidality
    • Suicide
    • Suvorexant
    • Symptom Assessment
    • Symptom Management
    • Systematic review
    • Tardive dyskinesia
    • Technology
    • Teen
    • teens
    • Telehealth
    • Telemed
    • Telemedicine
    • Telepsychiatry
    • test cme quiz
    • TGD
    • Therapy during medication appointment
    • Therapy with Med Management
    • TMS
    • Tobacco
    • tobacco research
    • Tobacco use disorder
    • Toxic Stress
    • Transcranial Magnetic Stimulation
    • Transdermal
    • Transgender
    • Translator
    • Trauma
    • Trauma Informed Care
    • Traumatic Brain Injury (TBI)
    • Trazodone
    • treatment
    • treatment pediatric
    • Treatment planning
    • Treatment-Resistant Depression
    • Trigeminal Nerve Stimulation
    • Trintellix
    • Understanding Psychiatric Research
    • Valbenazine
    • Vaping
    • Varenicline
    • Venlafaxine
    • videogaming addiction
    • Vitamin B6
    • Vitamin D
    • Vitamin E
    • VMAT2 Inhibitors
    • Vortioxetine
    • Vyleesi
    • Wakix
    • Weed
    • Weight gain
    • Weight Loss Medications
    • Wellbutrin
    • Wilderness Therapy Programs
    • Withdrawal
    • Women's Issues in Psychiatry
    • Women’s Issues in Psychiatry
    • Working With Families
    • Youth
  • HOME
  • STORE
  • CME CENTER
  • Blog
  • Podcast
  • NEWSLETTERS
    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
  • Archive
  • Archive
  • Archive
  • The Carlat Psychiatry Report
  • Bipolar Disorder (January)
  • The Bipolar Spectrum: Practical Tips for Diagnosis and Treatment

The Bipolar Spectrum: Practical Tips for Diagnosis and Treatment

The Carlat Psychiatry Report, Volume 16, Number 1, January 2018
https://www.thecarlatreport.com/newsletter-issue/tcprv16n1/

From The Carlat Psychiatry Report, January 2018, Bipolar Disorder

Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Topics: Bipolar Disorder | Free Articles

Print Friendly, PDF & Email

Chris Aiken, MD

Director of the Mood Treatment Center and instructor at the Wake Forest University School of Medicine. Co-author, with Jim Phelps, of Bipolar, Not So Much (W. W. Norton & Company).

Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Bipolar disorder has long been controversial in the field. Is it overdiagnosed or underdiagnosed? Does a “bipolar spectrum” truly exist, or is it a marketing tool for pharmaceutical companies that want you to prescribe more atypical antipsychotics?

At a minimum, the bipolar spectrum includes those patients who meet criteria for both bipolar I and II disorder, which accounts for roughly 16% of depressed patients. But DSM-5 changed that percentage drastically to include two new conditions on the spectrum: antidepressant-induced mania/hypomania and depression with mixed features.

Adding in these patients, the prevalence of bipolar spectrum among depressed patients skyrockets to 41%. Moreover, it rises to 47% when we include depressed patients with short-duration hypomania (a condition in the appendix of DSM-5). Those figures are estimates derived from two international studies with a total N of over 8,000 patients, and they are consistent with other estimates that place the bipolar spectrum at 40%–50% of depressed patients (Nusslock R and Frank E, Bipolar Disord 2011;13(7–8):587–603).

These figures may sound preposterously high to some clinicians, but to be clear, being on the bipolar spectrum is not the same as having “bipolar disorder.” Instead, it reflects the growing realization that mood disorders should not be split into arbitrary categories. Indeed, David Kupfer, the DSM-5 chair, wrote that depression and bipolar are part of “a continuum, with variable expressions of vulnerability to hypomania or mania” (Phillips ML and Kupfer DJ, Lancet 2013;11(381):1663–1671).

Clinically, what does all this mean? As a specialist in bipolar disorder, I am convinced that many more patients fit on the bipolar spectrum than we realize. In this article, I will describe five common types of patients who may not appear “bipolar” at first glance but who likely fall somewhere on the spectrum. If you can learn to recognize these patients, you will likely be able to fine-tune your treatment approach and have more therapeutic success.

Depressive mixed states

Typical patient statement
“It’s the worst depression I’ve ever had. I can’t shut my mind off—it races from one dreadful thought to another. The anxiety is unbearable. Everything gets on my nerves. I’m tired and depressed in the day, then wired at night—driven to do something, but I don’t know what to do.”

Diagnostic tips
The “mixed features specifier” in DSM-5 applies to unipolar and bipolar patients who have 3 or more manic symptoms during their depression. What does this mean? Patients with a history of unipolar depression and without a history of manic or hypomanic episodes do not qualify as bipolar disorder. However, many of these people will present with depressive episodes that include some manic symptoms. These are called “depressive mixed states.” Does this mean such patients are on the bipolar spectrum? In my view, it does, because you will treat them differently from patients who present with a standard depressive episode.

According to a meta-analysis involving 20,000 patients (Vázquez GH et al, J Affect Disord 2018;225:756–760), a significant minority of unipolar patients (25%) have depression with mixed features. Because they don’t look like the manic symptoms that we are used to seeing, these mixed-manic symptoms can easily be missed.

For example, when we think of elevated energy in bipolar disorder, we often think of increased productivity. But when mixed with depression, this energy leads to directionless, disorganized activity. Similarly, rather than experiencing an exciting flight of ideas, patients with mixed features have uncomfortable racing thoughts—usually depressive and anxious thoughts—that they desperately want to turn off.

Table: Table: Depression With Mixed Features Diagnostic Tips

Table: Depression With Mixed Features Diagnostic Tips
(Click to view Full-Size PDF)

Treatment recommendations
Recently, guidelines have been published for the treatment of depression with mixed features (Stahl SM et al, CNS Spectr 2017;22(2):203–219). Because essentially all the authors of these guidelines have financial relationships with pharmaceutical companies, we should take these recommendations with a grain of skepticism. Nonetheless, the article presents a good overview of the current research in the field, and the treatment recommendations are not unreasonable.

The authors recommend atypical antipsychotics as first-line treatments (specifically aripiprazole, asenapine, lurasidone, quetiapine, and ziprasidone). Second-line antipsychotics include cariprazine and olanzapine/fluoxetine combination (ie, Symbyax). Traditional mood stabilizers (lithium and the anticonvulsants) are second-line, and antidepressants are relegated to third-line therapies (even in unipolar patients with mixed depression) and only recommended in conjunction with mood stabilizers.

In actual practice, most patients are already on an antidepressant when their mixed features are discovered. The first step in such cases is to determine if the antidepressant is clearly helping the depression or contributing to the manic symptoms. If the antidepressant is helping, my policy is to leave it be and to monitor the patient closely. But if the antidepressant is aggravating manic symptoms, such as racing thoughts and insomnia, I will taper quickly over 1–2 weeks. Sometimes the antidepressant is simply ineffective, in which case I will usually taper it off, but more slowly (over 1–2 months).

In terms of antipsychotics, I am not nearly as enthusiastic about their use as the authors of the mixed depression guidelines. Although I acknowledge that some atypicals are “cleaner” than others in terms of side effects, I am concerned about the long-term risks of metabolic syndrome and tardive dyskinesia (the 1-year incidence of tardive dyskinesia on atypicals is estimated at 7%). Because of these concerns, I usually reserve atypicals for acute episodes and use traditional mood stabilizers, particularly lithium and lamotrigine, for long-term prevention. Lamotrigine is free of long-term risks; lithium, on the other hand, can cause a variety of problems such as hypothyroidism, weight gain, and (rarely) renal insufficiency. But with close monitoring, such problems can be minimized, and lithium has the extra added benefit of a clear antisuicide effect.

Psychotherapy should be considered for all cases of mixed depression. For all patients, whether in therapy or not, I emphasize a few lifestyle changes to help stabilize manic symptoms. Foremost is developing regular routines around sleep and waking. In the morning, patients should rise briskly out of bed (a dawn simulator can help) and start their day with an engaging activity. The evening routine should conjure sleep, with a relaxing activity, low lights, and an “electronics-free zone” in the half-hour before bed. Dark therapy, in which patients wear a $10 pair of blue-light filtering glasses in the evening and sleep in pitch darkness, is a new technique for mania that has shown promise in a small controlled trial of hospitalized patients.

Table: Recommended Treatment Options for Depression in Patients on the Bipolar Spectrum
Table: Recommended Treatment Options for Depression in Patients on the Bipolar Spectrum
(Click to view full-size PDF)

Cyclothymia with bipolar II

Typical patient statement
“My moods are all over the place. I don’t know what normal is. I hide it well—I can seem like the life of the party, but it’s really just an act. I have waves of anxiety, but other times I’m wide open. I’m usually great on a job when I first start—I’m full-throttle and get it all done—but after a few months, I burn out and can’t concentrate.”

Diagnostic tips
Around 40% of patients with bipolar II disorder have an underlying cyclothymic temperament. These patients have a stormier course than their classic bipolar II counterparts, who have productive, euphoric hypomanias and long periods of stable mood. In contrast, cyclothymic mood swings start early in life and are woven into patients’ temperament, allowing little time for a stable identity to develop. Euphoria is rare in these patients, and mixed states are common, with all the despairing, paradoxical symptoms described in the Diagnostic Tips table on page 2.

These patients have high rates of comorbidities, particularly borderline personality disorder, addictions, anxiety disorders, PTSD, OCD, ADHD, and eating disorders. Detecting bipolar symptoms amidst all these comorbidities is difficult, so the Bipolarity Index is particularly useful in this group; in one study, it outperformed other screening tools at distinguishing bipolar disorder from pure forms of Cluster B personality disorders. (Ed note: For more information on the Bipolarity Index, see this issue’s QA interview with Dr. Aiken).

Treatment
Psychotherapy should be part of the treatment for this group. Dialectical behavior therapy is often helpful, and it blends well with bipolar-specific therapies, which emphasize regular daily routines.

In terms of pharmacotherapy, it’s best to stabilize the bipolar disorder before treating the comorbidities, though this is a challenge as patients usually request treatment for the comorbidities first. Lamotrigine has the best evidence for cyclothymic disorder and is conveniently effective for borderline personality disorder as well. Many treatments for the comorbidities that are common in this group can destabilize mood, such as antidepressants and stimulants, but there are many that don’t. Below are some options with low risk of mood destabilization. Each is supported by at least one randomized controlled trial, and I’ve starred my top choice(s) in each category:

  • ADHD: clonidine*, guanfacine, modafinil/armodafinil*
  • Borderline personality disorder: lamotrigine* and other anticonvulsants, atypical antipsychotics, and omega-3 fatty acids
  • OCD: lamotrigine*, ondansetron, topiramate, memantine, and atypical antipsychotics
  • Anxiety: gabapentin*, pregabalin, clonidine, and propranolol, as well as complementary and alternative medicine therapies: silexan (lavender extract)*, chamomile, and probiotics

Depression with short-duration hypomania

Typical patient statement
Psychiatrist: “When you think about those elevated states—hyped up, sleeping less, talkative, irritable, or a bit impulsive—what’s the longest they’ve lasted?”

Patient: “Just a few hours.”

Psychiatrist: “I understand each of those symptoms can be brief and shift rapidly, but think carefully: have you ever been ‘that way’ for at least 4 days?”

Patient: “No, I’d say no more than 2–3 days.”

Diagnostic tips
Many patients with recurrent depression endorse clear hypomanic states that are just short of the 4-day duration required in the DSM, and these short-duration hypomanias are included in DSM-5 as a “condition for further study.” They are particularly common in adolescents who go on to develop full bipolar disorder, but short-duration hypomania can persist throughout life, and studies suggest that such cases represent an “intermediate phenotype” between unipolar and bipolar.

Treatment
One study supports lamotrigine for these patients, and this agent seems particularly effective in patients with quick, brief mood swings (McCraw S and Parker G, J Psychopharmacol 2016;30(6):554–558).

Antidepressants should be used with caution, though they are less risky here than they are in full bipolar disorder. In general, the more recent, more severe, and more frequent the manic symptoms, the greater the risks with antidepressants.

No mania vs. long-forgotten mania

Typical patient statement
“I’m not at all like my father—he had bipolar. I’m just depressed, but antidepressants never helped. I used a lot of drugs in my teens and 20s, but I’ve been sober now 30 years, and depressed for nearly all of them.”

Diagnostic tips
As you use the Bipolarity Index, you will encounter patients who deny manic symptoms but have multiple signs of bipolarity. These patients usually have recurrent depression and score in the 40–60 range on the Bipolarity Index. This is likely a mixed group including: 1) true unipolar depression; 2) older patients, who have forgotten their manias (pure mania is more prominent in young adulthood); and 3) younger patients, who are at high risk of conversion to bipolar disorder (see next section).

Treatment
There is not a clear treatment for these patients, but there is a definite need to watch carefully (particularly with antidepressants) and gather more information. Outside of antidepressants, I look for treatments that work in both unipolar and bipolar depression (see Recommended Treatment Options table on page 3).

The bipolar prodrome

Typical patient statement
“I have bipolar disorder, and I’m worried about my teenage son. He’s moody, depressed, and argumentative. He smokes a lot of weed and doesn’t care about his schoolwork. We’ve been to different doctors and they’ve diagnosed depression, social anxiety, and ADHD. The treatments seem to work at first, but they always wear off.”

Diagnostic tips
Bipolar is a highly genetic illness, and research is starting to identify the early, prodromal signs of the disorder. Those at highest risk are patients under age 25 who present with significant psychiatric symptoms and have a first-degree relative with bipolar disorder. It is the severity of the presenting symptoms that indicates the risk, rather than the type, as prodromal bipolarity can present as anxiety, ADHD, substance abuse, and nonspecific behavioral problems.

Treatment
Family therapy, which aims to improve communication and reduce levels of expressed emotion, has the best research support and is a first-line recommendation in a new treatment algorithm for prodromal bipolar disorder. In that algorithm, medications are only used if symptoms interfere with functioning, and antidepressants are not allowed if subsyndromal manic symptoms are present (if they are, mood stabilizers are used). Studies also support omega-3 fatty acids in this group.

TCPR Verdict: When evaluating depression, keep the bipolar spectrum in mind. Treatment informed by this approach might be more effective.

Suggested Articles

  • Differentiating Psychotic Disorders: Does It Matter? May 7, 2020 How do we understand the range of psychotic disorders in children and adolescents and how…
  • Communicating With Patients About Gender August 5, 2020 What are the risks for depression and suicide with transgender patients and how can we…

Powered by Contextual Related Posts

Share this page!
Subscribe
Register for free content

Register For Free Articles

Register to receive free email newsletters with concise, practical advice for busy clinicians. You will also have access to select article content on the website and you will receive notifications of new books and special discount offers.




Courses and Book CME
Psychiatry Practice Boosters, Third Edition (2021)
The Medication Fact Book for Psychiatric Practice, Fifth Edition (2020)
2021 Carlat Psychiatry Report Self-Assessment Course
2020 Carlat Psychiatry Report Self-Assessment Course
The Child Medication Fact Book for Psychiatric Practice (2018)
Issue Archives

2021

  • Mind-Gut Connection (January)

2020

  • Esketamine (January)
  • Telepsychiatry (May)
  • Mind-Gut Connection (January)
  • Practical Psychotherapy (November/December)
  • Mood and Menopause (October)
  • When to Use Lithium (September)
  • Traumatic Brain Injury (August)
  • Borderline Personality Disorder (June/July)
  • Psychopharmacology Algorithms (April)
  • Bipolar II (March)
  • Inflammation and Depression (February)

2020

  • Mood Disorders in Children and Adolescents (Oct/Nov/Dec)
  • Identity & Culture in Children and Adolescents (July/August/September)
  • Psychosis in Children and Adolescents (April/May/June)
  • ADHD in Children and Adolescents (Jan/Feb/Mar)

2020

  • Harm Reduction (January/February)
  • Substance Use in Health Professionals (March/April)
  • Alternative Treatment in Addiction (November/December)
  • Social Aspects of Addiction (September/October)
  • Opioid Use Disorder Treatment (July/August)
  • Emerging Risks for Old Medications (May/June)

2019

  • Depression (May)
  • Adult ADHD (November/December)
  • Mental Health Apps (October)
  • How to Talk about Medication (September)
  • Side Effects Part II (August)
  • Side Effects Part I (June/July)
  • Sleep (April)
  • Parenting, Pregnancy, and Prevention (March)
  • Dark and Light Therapy (February)
  • Deprescribing (January)

2018

  • Drug Metabolism (November/December)
  • Working With Transgender Patients (October)
  • Emergency Psychiatry (September)
  • Treatment-Resistant Depression (July/August)
  • Neurobiology (June)
  • Anxiety (May)
  • Neurofeedback (April)
  • Antipsychotics Update (March)
  • Working With Families (February)
  • Bipolar Disorder (January)

2017

  • PTSD (December)
  • Retirement (November)
  • Intellectual Disability (September/October)
  • Antidepressants (July/August)
  • Personality Disorders (June)
  • Dementia (May)
  • Cognitive Behavior Therapy Techniques (April)
  • Pharmacogenetics (March)
  • Treating Psychosis (February)
  • Adult ADHD (January)

2016

  • Complementary and Alternative Medicine in Psychiatry (November/December)
  • Side Effects (October)
  • Pain Management (September)
  • Medication in Pregnancy (July/August)
  • Psychoanalysis in Modern Psychiatry (June)
  • Correctional Psychiatry (May)
  • Antidepressant Roundup (April)
  • Burnout (March)
  • Private Practice (February)
  • Bipolar Disorder (January)

2015

  • Psychiatry and General Medicine (November/December)
  • Biomarkers in Psychiatry (May)
  • Telepsychiatry (October)
  • Sleep Disorders (September)
  • Interventional Psychiatry (July/August)
  • Eating Disorders (June)
  • Psychotherapy Updates (April)
  • Topics in Geriatric Psychiatry (March)
  • Antipsychotics Update (February)
  • Risk Management (January)

2014

  • Bipolar Disorder (November/December)
  • Pharmacogenetics (October)
  • Keeping up in Psychiatry (September)
  • Research in Psychiatry (July/August)
  • Marijuana (June)
  • Psychiatric Diagnosis (May)
  • Issues in Psychopharmacology (April)
  • Schizophrenia (March)
  • Women’s Psychiatry (February)
  • Ethics in Psychiatry (January)

2013

  • Military Psychiatry (December)
  • Depression (November)
  • Treatment of Dementia (October)
  • Anxiety Disorders (September)
  • Natural and Alternative Treatments in Psychiatry (July/August)
  • Autism Spectrum Disorder (June)
  • Practice Tips (May)
  • Substance Abuse (April)
  • Medicolegal Topics (March)
  • End of Life Care (February)
  • Antipsychotic Update (January)

2012

  • Screening Tools and Tips (December)
  • Medical Comorbidities (November)
  • Devices in Psychiatry (October)
  • Eating Disorders (September)
  • Bipolar Disorder (July/August)
  • Risk Management (June)
  • Antidepressant Roundup 2012 (May)
  • Gender and Sexuality (April)
  • Personality Disorders (March)
  • ADHD (February)
  • Natural Treatments in Psychiatry (January)

2011

  • Electronic Medical Records (December)
  • Insomnia (November)
  • Psychotherapy (October)
  • Alcoholism (September)
  • Anxiety Disorders (July/August)
  • Schizophrenia (June)
  • Managing Side Effects (May)
  • Antidepressant Roundup 2011 (April)
  • DSM-5 and Diagnostic Issues (March)
  • Drug-Drug Interactions (February)
  • Bipolar Disorder (January)

2010

  • Hospital Psychiatry (December)
  • Psychiatric Medication in Pregnancy (November)
  • Maintenance of Certification (October)
  • The Neuroscience of Psychotherapy (September)
  • Treatment of Depression (July/August)
  • Email and the Internet in Psychiatry (June)
  • Substance Abuse (May)
  • The Diagnosis and Treatment of Dementia (April)
  • Ethics in Psychiatry (March)
  • Natural Treatments in Psychiatry (February)
  • ADHD (January)

2009

  • Treating Schizophrenia (December)
  • Treatment for Anxiety Disorders (November)
  • The Latest on Antidepressants (October)
  • Topics in Neuropsychiatry (September)
  • The Interface of Medicine and Psychiatry (July/August)
  • Generic Medications in Psychiatry (June)
  • The Treatment of Eating Disorders (May)
  • Healthcare Policy and Psychiatry (April)
  • Antipsychotic Roundup 2009 (March)
  • Psychiatric Medication in Pregnancy and Lactation (February)
  • Transcranial Magnetic Stimulation (January)

2008

  • Treating Fibromyalgia and Pain in Psychiatry (December)
  • Issues in Child Psychiatry (November)
  • Improving Psychiatric Practice (October)
  • Treating Personality Disorders (September)
  • Bipolar Disorder (July/August)
  • Antipsychotic Roundup 2008 (June)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Neuropsychological Testing (May)
  • Psychiatric Medications: Effects and Side Effects (April)
  • Update on Substance Abuse (March)
  • Anticonvulsants in Psychiatry (February)
  • Brain Devices in Psychiatry (January)

2007

  • The Treatment of Insomnia (December)
  • Avoiding Malpractice in Psychiatry (November)
  • Update on Eating Disorders (October)
  • Complex Psychopharmacology (September)
  • Laboratory Testing in Psychiatry (August)
  • Psychotherapy in Psychiatry (July)
  • Posttraumatic Stress Disorder (June)
  • Topics in Geriatric Psychiatry 2007 (May)
  • Pregnancy and Menopause in Psychiatry (Apil)
  • Antipsychotic Roundup 2007 (March)
  • Understanding Psychiatric Research (February)
  • Antidepressant Round-up 2007 (January)

2006

  • Technology and Psychiatric Practice (December)
  • The Use of MAOIs (November)
  • Medication Treatment of Depression (January)
  • Seasonal Affective Disorder (October)
  • Treatment of ADHD (September)
  • Topics in Bipolar Disorder (August)
  • Neurotransmitters in Psychiatry (July)
  • Treating Substance Abuse (June)
  • The STAR*D Antidepressant Trial (May)
  • Natural Treatments in Psychiatry (April)
  • Medication Treatment of Anxiety (March)
  • Panic Disorder: Making Treatment Work (March)
  • Antipsychotic Roundup 2006 (February)
  • Antidepressant Roundup 2006 (January)

2005

  • Self-Help Books and Psychiatry (December)
  • Genetics and Psychiatry (November)
  • Pregnancy and Psychiatric Treatment (October)
  • Benzodiazepines and Hypnotics in Psychiatry (September)
  • Geriatric Psychiatry Update (August)
  • Chart Documentation in Psychiatry (July)
  • The Treatment of Bipolar Disorder (June)
  • Weight Loss and Smoking Cessation in Psychiatry (May)
  • Treating ADHD (April)
  • Drug Industry Influence in Psychiatry (March)
  • Atypical Antipsychotics 2005 (February)
  • Antidepressant Roundup 2005 (January)

2004

  • Sexual Dysfunction (December)
  • Suicide Prevention (November)
  • To Sleep, To Awake (October)
  • Women’s Issues in Psychiatry (September)
  • OCD: An Update (August)
  • Chronic Pain and Psychiatry (July)
  • Neuroimaging in Psychiatry (June)
  • Natural Medications in Psychiatry (May)
  • Posttraumatic Stress Disorder (April)
  • Treatment of Alcoholism (March)
  • Battle of the Atypicals (February)
  • Antidepressant Roundup, 2004 (January)

2003

  • Research Methods in Psychiatry (December)
  • Antidepressants in Children (November)
  • The Treatment of Dementia (October)
  • Bipolar Disorder, Part II: The Novel Anticonvulsants (September)
  • Bipolar Disorder: The Basics (August)
  • Drug-Drug Interactions in Psychiatry (July)
  • Managing Antidepressant Side Effects (June)
  • Antidepressants in Pregnancy and Lactation (May)
  • ADHD: Medication Options (April)
  • Panic Disorder: Making Treatment Work (March)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Medication Treatment of Depression (January)

2019

  • Autism in Children and Adolescents (November/December)
  • Depression in Children and Adolescents (May/June/July/August)
  • Substance Use in Children and Adolescents (September/October)
  • Trauma in Children and Adolescents (March/April)
  • Anxiety in Children and Adolescents (January/February)

2018

  • Psychotropic Risks in Children and Adolescents (May/June)
  • ADHD in Children and Adolescents (November/December)
  • Depression in Children and Adolescents (September/October)
  • Autism in Children and Adolescents (July/August)
  • Anxiety in Children and Adolescents (March/April)
  • Suicide in Children and Adolescents (January/February)

2017

  • Adolescents (November/December)
  • ADHD in Children and Adolescents (September/October)
  • Psychosis in Children and Adolescents (August)
  • PANDAS, PANS, and Related Disorders (June/July)
  • Marijuana in Children and Adolescents (May)
  • Tourette’s and Other Tic Disorders in Children and Adolescents (March/April)
  • Autism in Children and Adolescents (January/February)

2016

  • Gender Dysphoria in Children and Adolescents (November/December)
  • Technology Issues With Children and Adolescents (September/October)
  • Mood Dysregulation in Children and Adolescents (July/August)
  • Eating Disorders in Children and Adolescents (May/June)
  • Conduct Disorder in Children and Adolescents (April)
  • Sleep Disorders in Children and Adolescents (March)
  • ADHD in Children and Adolescents (January/February)

2015

  • Antidepressant Use in Children (November/December)
  • Foster Care and Child Psychiatry (September/October)
  • Autism (July/August)
  • Trauma (May/June)
  • Anxiety Disorders (April)
  • Schools and Psychiatry (March)
  • Emergency Psychiatry in Children (January/February)

2014

  • Antipsychotics in Children (December)
  • ADHD (November)
  • Gender and Sexuality (September/October)
  • Psychotic Symptoms (Summer)
  • Medication Side Effects (May)
  • Food and Mood (April)
  • Learning and Developmental Disabilities (February)

2013

  • Complex Practice Issues (December)
  • Diet and Nutrition (November)
  • Child Psychiatry in DSM-5 (August/September)
  • Medication Side Effects and Interactions (June/July)
  • Problematic Technology (March/April)
  • Autism Spectrum Disorders (January/February)

2012

  • Bipolar Disorder (December)
  • Substance Abuse (October/November)
  • Transitional Age Youth (July/August)
  • Rating Scales (May/June)
  • Eating Disorders (March/April)
  • Behavioral Disorders (February)

2011

  • Treatment of Anxiety Disorders (December)
  • Trauma (November)
  • Bullying and School Issues (October)
  • Hidden Medical Disorders (August)
  • OCD and Tic Disorders (June)
  • Suicide and Non-Suicidal Self Injury (April)
  • Sleep Disorders (March)
  • ADHD (January)

2010

  • Use of Antipsychotics in Children and Adolescents (December)
  • Learning and Developmental Disabilities (October)
  • Major Depression (September)
  • Treating Children and Families (July)
  • The Explosive Child (May)

2019

  • Dual Diagnosis in Addiction Medicine (May/June)
  • Medical Issues in Addiction Practice (November/December)
  • Alcohol Addiction (September/October)
  • Legal Issues in Addiction Medicine (July/August)
  • Traumatic Brain Injury and Addiction (March/April)
  • Board Certification in Addiction Medicine (January/February)

2018

  • Opioid Addiction (November/December)
  • Addiction in Older Adults (October)
  • Sleep Disorders and Addiction (September)
  • Adolescent Addiction (July/August)
  • Pain and Addiction (May/June)
  • Cannabis and Addiction (March/April)
  • Stigma and Addiction (January/February)

2017

  • Pregnancy and Addiction (November/December)
  • Detox (Sepember/October)
  • Dual Diagnosis (August)
  • Alternatives to 12-Step Programs (June/July)
  • Recovery (May)
  • Psychiatric Uses of Street Drugs (March/April)
  • Sex Addiction (January/February)

2016

  • Prescription Drug Monitoring Programs (PDMPs) (November/December)
  • Addiction in Health Care Professionals (September/October)
  • Dialectical Behavior Therapy in Addiction (August)
  • Motivational Interviewing (June/July)
  • Benzodiazepines (May)
  • Opioid Addiction (March/April)
  • Families and Substance Abuse (January/February)

2015

  • The Twelve Steps (November/December)
  • Designer Drugs (September/October)
  • Residential Treatment Programs Decoded (July/August)
  • Nicotine and E-Cigarettes (June)
  • Drug Screening (April/May)
  • Integrating Therapy and Medications for Alcoholism (March)
  • Detoxification Protocols (January/February)

2014

  • Behavioral Addictions (December)
  • Risk and Reimbursement (November)
  • Stimulant Abuse (September/October)
  • Self-Help Programs (June)
  • Opioid Addiction (May)
  • Coping with Bad Outcomes (March)
  • Change Management in Addiction Treatment (January/February)

2013

  • Cocaine Addiction (December)
  • Relapse Prevention (November)
  • Cannabis Addiction (August/September)
  • Addiction in DSM-5 (June/July)
Editor-in-Chief

Chris Aiken, MD

Dr. Aiken is the director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice.

Full Editorial Information

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Subscriptions
  • Books
  • Online Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Child Psychiatry Report

Contact

  • info@thecarlatreport.com
  • 866-348-9279
  • PO Box 626, Newburyport MA 01950

Follow Us

© 2021 Carlat Publishing, LLC and Affiliates, All Rights Reserved.

Please see our Privacy Policy and the Hardware/Software Requirements to view our website.

×